05.07.2022 09:10
Basel-based VectivBio is focused on novel treatments for severe rare conditions. Its lead molecule is already in Phase 3 Clinical Trials. VectivBio has closed each of its previously announced public offering of 6,467,688 ordinary shares, including its previously announced private placement for the sale of 3,478,260 ordinary shares to Forbion’s Growth Opportunities Fund II.